Erythropoietin News and Research

RSS

Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.

High erythropoietin levels predict higher mortality

High erythropoietin levels in people over age 85 indicate a higher risk of death, according to a study published in CMAJ.

26 Oct 2010

Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries

Affymax, Inc. today announced that it has received a decision from the arbitration panel reviewing its dispute against certain subsidiaries of Johnson and Johnson (JNJ).

7 Oct 2010

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.

7 Oct 2010

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone for the treatment of growth hormone deficiency.

5 Oct 2010

Hospira's Nivestim receives Australian TGA approval

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration approval for its biosimilar filgrastim product, Nivestim.

27 Sep 2010

FG-4592 oral anemia therapy receives CTA approval from SFDA

FibroGen, Inc., today announced that its investigational oral anemia therapy, FG-4592, received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to commence clinical development for the treatment of anemia associated with chronic kidney disease (CKD) in the People's Republic of China.

21 Sep 2010

Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction

Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.

30 Aug 2010

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

24 Aug 2010

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

5 Aug 2010

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.

2 Aug 2010

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.

29 Jul 2010

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

26 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.

17 Jul 2010

PROLOR Biotech receives EU GMP certification for hGH-CTP biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received formal Good Manufacturing Practice (GMP) certification for hGH-CTP, the company's proprietary biobetter version of human growth hormone. GMP certification is required by the European Union (EU) clinical trials legislation as a precondition for conducting clinical trials in EU member countries.

29 Jun 2010

June issue of Clinic Women's HealthSource provides overview of anemia

Anemia is not a normal part of aging, yet it's fairly common in older adults and causes frailness, weakness and increased risk of falls. According to Mayo Clinic Women's HealthSource, more than one in 10 older adults has anemia. Twenty percent of women are anemic by age 85.

24 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

EC approves Nivestim for prevention of FN

Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.

10 Jun 2010

TASE approves new listing of PROLOR Biotech's common stock

PROLOR Biotech, Inc.,, a company developing next generation biobetter therapeutic proteins, today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of PROLOR's common stock on the TASE beginning on Thursday, May 27, 2010. At that time, the company's common stock will be listed on both the NYSE Amex in the United States and the TASE in Israel.

26 May 2010

Researchers study how hematopoietic cells react when Epo levels increase

Our body reacts to blood loss by stimulating the production of red blood cells (erythrocytes). The cells of the hematopoietic (blood-forming) system in the bone marrow do so upon receipt of a signal by a hormone called erythropoietin, or Epo for short. This hormone is produced mainly by the kidney that increases the Epo level by up to a thousand-fold as a response to falling oxygen saturation of the blood.

25 May 2010